December 2022, Hangzhou Adcoris Biopharma Co., LTD.(Adcoris) and Lunan Pharmaceutical Group (Lunan) announced that a strategic collaboration agreement was reached on the joint development of one to two ADC products. According to the agreement, Adcoris and Lunan will leverage their respective advantages to collaborate on the development of at least one ADC drug, evaluate its preclinical and clinical effects and commercialize the product in great China and worldwide.

As a result of this partnership, Adcoris will receive an upfront payment, multiple milestone payments and a corresponding share of future product commercialization revenue.

This collaboration is the first for Adcoris and a recognition of Adcoris’ platform technology by a big pharmaceutical company. It is highly anticipated that this strategic collaboration between the two companies will generate great synergies in the development process and provide better medical solutions to satisfy the clinical unmet need in cancer treatment.